Skip to content

LUNA-EMG to Enhance Motor Functions in Multiple Sclerosis

LUNA-EMG to Enhance Lower Limb Motor Functions in Multiple Sclerosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04720898
Acronym
LUNA-MS
Enrollment
42
Registered
2021-01-22
Start date
2021-03-01
Completion date
2024-06-01
Last updated
2025-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

The aim of the present study is to evaluate the effects of training performed with the LUNA-EMG system to enhance motor functions of the lower limb in multiple sclerosis. This is a randomized open-label trial. Patients will be randomized into the intervention group (LUNA-EMG, 30-45 minutes once a week for 12 weeks) or in the control group (standard care). The effect of the training will be measured based on the muscular strength, walking tests, proprioception and a quality of life questionnaire.

Interventions

DEVICELUNA-EMG

The LUNA-EMG (Samcom) system is a robot that allows the evaluation of muscular strength through the recording of muscle activity (electromyography - EMG) in order to provide precise objective data on the patient's muscle function. In addition to the diagnostic aspect (evaluation of muscle strength, range of motion and proprioception), the LUNA-EMG robot provides optimized range of motion's movements and a visual feedback on the patient's performance. In addition, it may enhance neuroplasticity due to the increased number of movements repetitions which could influence motor learning.

Sponsors

University of Liege
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* EDSS less or equal to 6.5 * Between 18 and 70 years old * Having signed the informed consent

Exclusion criteria

* Acute pain syndrome * Severe cognitive deficits * Risk of fracture or unconsolidated fracture * Rigid joints (spasticity, severe osteoarthritis and arthritis) or unstable joints * Severe ataxia and apraxia * Epilepsy * Pacemakers and similar implants * Insufficient skin conditions

Design outcomes

Primary

MeasureTime frameDescription
Muscle strength in mV12 weeksMuscular strength is measured with a dynamometer.

Secondary

MeasureTime frameDescription
Proprioception12 weeksPatients proprioception will be measured with the LUNA system. It calculates the distance in degree (°) between the target arm position and the arm position that the patient try to reproduce. Lower degree represent a more accurate positioning of the arm by the patient.
Timed 25-Foot Walk, seconds12 weeksThe patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The faster the better.
Timed Up and Go, seconds12 weeksThe person must get up from the seated position and walk three meters away from the chair and then retrace their steps (turn 180 degrees) and sit down again. The faster the better.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026